Article ID Journal Published Year Pages File Type
2880907 The Annals of Thoracic Surgery 2008 8 Pages PDF
Abstract
Tetrathiomolybdate has antiangiogenic effects in malignant pleural mesothelioma patients after resection of gross disease, and exhibits minimal toxicity and comparable efficacy to previous multimodality trials. Tetrathiomolybdate should be evaluated for efficacy in combination with standard malignant pleural mesothelioma regimens, as well as for postsurgical maintenance therapy.
Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Preview
A Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final Results
Authors
, , , , , , ,